Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
Mirum Pharmaceuticals (MIRM) Stock Price & Analysis
437 Followers
MIRM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$17.32 - $30.55
Previous Close$23.04
Volume185.82K
Average Volume (3M)314.45K
Market Cap
$874.39M
Enterprise Value$724.86M
Total Cash (Recent Filing)$151.72M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)-5.7
Beta0.57
Next Earnings
May 04, 2023EPS Estimate
-$0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.02
Shares Outstanding36,870,380
10 Day Avg. Volume238,986
30 Day Avg. Volume314,454
Standard Deviation0.41
R-Squared0.03
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)7.07
Price to Sales (P/S)17.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-10.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.41
Enterprise Value/Gross Profit11.21
Enterprise Value/Ebitda-5.92
Forecast
1Y Price Target
$54.67Price Target Upside131.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Mirum Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MIRM FAQ
What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?
Mirum Pharmaceuticals Inc lowest stock price was $17.32 and its highest was $30.55 in the past 12 months.
What is Mirum Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?
Mirum Pharmaceuticals Inc’s upcoming earnings report date is May 04, 2023 which is in 44 days.
How were Mirum Pharmaceuticals Inc’s earnings last quarter?
Mirum Pharmaceuticals Inc released its earnings results on Mar 08, 2023. The company reported -$0.99 earnings per share for the quarter, beating the consensus estimate of -$1.004 by $0.014.
Is Mirum Pharmaceuticals Inc overvalued?
According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued.
Does Mirum Pharmaceuticals Inc pay dividends?
Mirum Pharmaceuticals Inc does not currently pay dividends.
What is Mirum Pharmaceuticals Inc’s EPS estimate?
Mirum Pharmaceuticals Inc’s EPS estimate is -$0.82.
How many shares outstanding does Mirum Pharmaceuticals Inc have?
Mirum Pharmaceuticals Inc has 37,950,970 shares outstanding.
What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?
Mirum Pharmaceuticals Inc reported an EPS of -$0.99 in its last earnings report, beating expectations of -$1.004. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?
Among the largest hedge funds holding Mirum Pharmaceuticals Inc’s share is Deerfield Management Company, LP. It holds Mirum Pharmaceuticals Inc’s shares valued at 40M.
---
Mirum Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.67 (131.65% Upside)
$54.67 (131.65% Upside)
Blogger Sentiment
Bullish
MIRM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.9%
Last 30 Days ▲ 19.3%
Last 30 Days ▲ 19.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.17%
12-Months-Change
Fundamentals
Return on Equity
-103.46%
Trailing 12-Months
Asset Growth
19.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.
---
4D Molecular Therapeutics
―
POINT Biopharma Global
―
Anavex Life Sciences
―
iTeos Therapeutics
―
CTI BioPharma
―
---